Transgene FY26 H1 net loss narrows 18.79% to €15.67 million
Bitget2026/09/24 15:45- Transgene posted a net loss of EUR 15.67 million for H1 2026, narrowing from EUR 19.3 million a year earlier.
- Operating loss narrowed to EUR 16.74 million, while operating income fell 34.64% to EUR 2.99 million.
- Cash and equivalents totaled EUR 92.8 million at June 30, down from EUR 111.9 million at Dec. 31.
- Cash burn rose to EUR 20.3 million, and financial visibility was reiterated through early 2028 under current plans.
- TG4050 Phase 2 recruitment finished, TG4070 Phase 1 started, and TG-MVA advanced toward clinical development on positive preclinical data.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
WikiLeaks Founder Julian Assange Welcomes Daughter With Terminator Quote
Crypto prices
More
